Hormone therapy for menopause: Current status;Hormontherapie um die Menopause: Ein aktueller Blick

Internist

Volumn 44, Issue 12, 2003, Pages 1500-1507

  Seifert Klauss, V ^a   Schumm Draeger, P M ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Stadt Krankhs Munchen Bogenhausen   (Germany)

Author keywords

Cardiovascular disease; Hormone replacement therapy; Osteoporosis; Perimenopause Postmenopause

Indexed keywords

ESTROGEN; GESTAGEN;

ALZHEIMER DISEASE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FEMALE; GERMANY; HEART INFARCTION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; OSTEOPOROSIS; POSTMENOPAUSE; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT CONTRAINDICATION;

AGED; BREAST NEOPLASMS; CLIMACTERIC; CLINICAL TRIALS; CORONARY THROMBOSIS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INTRACRANIAL EMBOLISM; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; TREATMENT OUTCOME;

EID: 0346881646     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-003-1080-8     Document Type: Review

References (31)

1. Barrett-Connor E, Slone St, Greendale G et al. (1997) The postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women. Maturitas 27:261-274
2. Beral V for the Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427
3. Black DM, Thompson DE, Bauer DC et al. for the FIT Research Group (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 85:4118-4124
4. Calle EE, Mirade-Mcmahill HL, Thun M, Henth CW (1995) Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 87:517-527
5. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML et al. for the WHI Investigators (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. JAMA 289: 3243-3253
6. Ferrara A, Quesenberry CP, Karter AJ, Njoroge CW, Jacobson AS, Selby JV (2003) Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes. The Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation 107:43-48
7. Flesch-Janys D, Köchel A, Koch P, Berger J, Braendle W (2001) Prävalenz postmenopausaler Hormonsubstitution in Hamburg am Beispiel der Verordnungsdaten der AOK 1998 und TK 1999. Geburtsh Frauenheilk 61: 995-1000
8. Grady D, Herrington D, Bittner V et al for the HERS Research Group (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacemt Study Follow-up (HERS II). JAMA 288:49-57
9. Grodstein F, Martinez MJ, Platz EA (1998) Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 128:705-713
10. Grodstein F, Newcomb PA, Stampfer, M (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis. Am J Med 109: 574-582
11. Grodstein F, Stampfer MJ, Manson JE et al. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335:453-461
12. Guyatt GH, Cranney A, Griffith L, Walter S, Krolicki N, Favus M, Rosen C (2002) Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin N Am 31:659-679
13. Hays J, Ockene JK, Brunner RL et al. for the Women's Health Initiative Investigators (2003) Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348:1839-1854
14. Hale GE, Hughes CL, Cline JM (2002) Endometrial cancer: hormonal factors, the perimenpausal "window of risk" and isoflavones. J Clin Endocrinol Metab 87:3-15
15. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM (1996) Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981-983
16. Modelska K, Cummings S (2002) Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87:16-23
17. Newcomb PA, Trenthan-Dietz A, Egan KM, Titus-Ernstoff L, Baron JA, Storer Willett WC, Stampfer MJ (2001) Fracture history and risk of breast and endometrial cancer. Am J Epidemiol 153:1071-1078
18. Perez Gutthann S, Rodriguez LAG, Castelsague J, Oliart AD (1997) Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 14:796-800
19. Rapp SR, Espeland MA et al. for the WHIMS Investigators (2003) Effect of estrogen plu progestin on global cognitive funtion in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289:2663-2672
20. Rosano GMC, Mercuro G, Vitale C, Rossini P, Galetta P, Fini M (2001) How progestins influence the cardiovasular effect of hormone replacement therapy. Gynecol Endocrinol 15 (Suppl 6):9-17
21. Santen RJ, Pinkerton J, McCartney C, Petroni GR (2001) Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 86:16-23
22. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL (2002) Pathophysiology and treatment of hot flushes. Mayo Clin Proc 77:1207-1218
23. Sherwin B (2003) Estrogen and cognitive functioning in women. Endocr Rev 24:133-151
24. Shumaker SA, Legault C et al for the WHIMS Investigators (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651-2662
25. Siris ES, Miller PD, Barrett-Connor E et al. (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results from the National Osteoporosis Risk Assessment. JAMA 286:2815-2822
26. Skafar DF, Xu R, Morales J, Ram J, Sowers JR (1997) Clinical review 91: female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 82: 3913-3918
27. Slattery ML, Potter JD, Curtin K (2001) Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res 61: 126-134
28. Wassertheil-Smoller S, Hendrix SL et al. for the WHI Investigators (2003) Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA 289: 2673-2684
29. Woodson K, Lanza E, Tangrea A (2001) Hormone replacement therapy and colorectal adenoma among women in the Polyp Prevention Trial. J Natl Cancer Inst 93: 1799-1810
30. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 288:321-333
31. Zhang Y, Kiel DP, Kreger B et al. (1997) Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336:611-617